Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15910932 | 0.73 | ALDH1A1 (0.40) | ALDH1A1LMNAKCNH2RXFP1FDPS | |
| SCHEMBL355054 | 0.73 | ALDH1A1 (0.50) | ALDH1A1LMNARXFP1FDPSRAB9A | |
| SCHEMBL14839426 | 0.72 | ALDH1A1 (0.40) | ALDH1A1LMNAKCNH2RXFP1FDPS | |
| SCHEMBL19463070 | 0.70 | HIF1A (0.38) | ALDH1A1LMNARXFP1GAAKCNJ5 | |
| SCHEMBL29379720 | 0.70 | HIF1A (0.38) | ALDH1A1LMNARXFP1GAAKCNJ5 | |
| SCHEMBL30094777 | 0.69 | KMO (0.41) | ALDH1A1RXFP1 | |
| SCHEMBL1557065 | 0.69 | KMO (0.41) | ALDH1A1RXFP1 | |
| SCHEMBL14839422 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNAKCNH2RXFP1FDPS | |
| SCHEMBL14839431 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNAKCNH2RXFP1FDPS | |
| SCHEMBL29501850 | 0.66 | RAB9A (0.47) | ALDH1A1RXFP1FDPSRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2762479-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013044845-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | 山东轩竹医药科技有限公司 (CN) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | OXA1L, CYP2C19, CBR3 | ALDH1A1 721/4885LMNA 3145/4885KCNH2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.